Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Thomson Reuters Stock Report
Provider: ValuEngine, Inc.
Provider: Pechala's Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Uroplasty Inc reaffirms FY 2015 guidance - Conference Call

Thursday, 24 Jul 2014 04:30pm EDT 

Uroplasty Inc:Continues to expect FY 2015 total revenue growth to range from 9pct to 12pct.Continues to expect cash operating loss for FY 2014 to be between $3 million and $4 million.FY 2015 revenue of $27 million - Thomson Reuters I/B/E/S. 

Company Quote

0.05 +4.13%
9:34am EST